January 17, 2019
Neurocrine Biosciences’ Ingrezza allows patients use existing medications with no clinically meaningful changes in psychiatric stability
Neurocrine Biosciences, published a new analysis of Ingrezza (valbenazine) capsules, in the Journal of Affective Disorders, pointing out improvement in tardive dyskinesia (TD) symptoms in patients with primary mood disorders, with no clinically meaningful changes to psychiatric stability.
